SwanBitcoin445X250

BERLIN (Reuters) - Bayer (BAYGn.DE) launched a 6 billion euros ($7 billion) rights issue on Sunday, a cornerstone of the financing package for its planned $62.5 billion takeover of seeds maker Monsanto (MON.N).

image
FILE PHOTO: The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal, Germany February 24, 2014. REUTERS/Ina Fassbender/File Photo/File Photo

Bayer last week won U.S. approval for the Monsanto takeover, clearing a major hurdle for a deal that will create by far the largest seeds and pesticides maker.

The cash call is smaller than initially envisaged by Bayer because Monsanto reduced its debt while the antitrust review dragged on.

image
FILE PHOTO: Werner Baumann, CEO of German pharmaceutical and chemical maker Bayer AG, and Werner Wenning, chairman of Bayer's supervisory board, shake hands before the annual general shareholders meeting in Bonn, Germany, May 25, 2018. REUTERS/Wolfgang Rattay

Also, Bayer raised 4.5 billion euros more from selling down its stake in plastics maker Covestro (1COV.DE) than initially expected.

The German drugmaker also grossed 7.6 billion euros in proceeds from selling assets to BASF (BASFn.DE), as the antitrust reviews were stricter than anticipated, but that did not cut the need to raise money via a share issue because future cash flows to service debts would also be lower.

When the merger was agreed in September 2016, Bayer said it would raise $19 billion worth of fresh equity capital for the takeover deal, parts of which was covered by issuing 4 billion euros in mandatory convertible notes in November 2016.

Bayer has said it would close the transaction very soon, which it needs to do because Monsanto could withdraw from the takeover agreement and seek a higher price after June 14.

Read more from our friends at Reuters: